CVS

Business Context and Reporting Period

Company: CVS Corporation (now CVS Health Corp)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Thirteen weeks ended April 1, 2006
Business Overview: The largest retail pharmacy in the U.S. operating 5,483 retail and specialty drug stores across 37 states and D.C. The company operates two primary segments: Retail Pharmacy and Pharmacy Benefit Management (PBM).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8.7% year-over-year, driven by a 9.4% increase in pharmacy sales and a 6.8% increase in front store sales. Same-store sales rose 6.2%.
• Profitability: Net earnings increased 13.8% to $329.6 million. Gross margin percentage improved to 26.6% from 25.9%, aided by higher generic drug sales and reduced inventory losses.
• Cash Flow: Operating cash flow surged to $171.7 million from $42.8 million, primarily due to increased cash receipts from sales.
• Debt Structure: Short-term debt increased significantly to $512.0 million (up from $253.4 million) to fund operations and prepare for acquisitions, while long-term debt remained relatively stable after the repayment of $300 million in senior notes.
• Accounting Changes: Adoption of SFAS No. 123(R) regarding share-based payments resulted in a $9.6 million reduction in net earnings and an increase in the effective tax rate to 38.9%.

Outlook, Risks, and Unusual Items

Major Acquisition

On January 22, 2006, CVS entered a definitive agreement to acquire approximately 700 standalone Sav-on and Osco drugstores and a distribution center from Albertson's, Inc. for $3.93 billion in cash. The transaction is expected to close in early June 2006, subject to regulatory and shareholder approvals. Financing will involve cash, short-term debt, and long-term debt, with plans to monetize real estate via sale-leaseback transactions for up to $1.0 billion.

Guidance and Commentary

Management anticipates that cash flows from operations and borrowings will fund future growth and the Albertson's transaction. The company expects to refinance a portion of short-term borrowings with longer-term financing in the third quarter of 2006. To manage interest rate risk, the company entered into forward starting pay fixed rate swaps with a notional amount of $570 million.

Risks and Contingencies

• Credit Ratings: In April 2006, Moody's lowered senior unsecured ratings to Baa1, and Standard & Poor's lowered corporate credit and senior unsecured debt ratings to BBB+, citing the capital structure changes related to the Albertson's acquisition. Both remain investment grade.
• Regulatory Environment: Risks include the introduction of Medicare Part D, which may decrease pharmacy gross margin rates, and the Deficit Reduction Act of 2005, expected to reduce Medicaid reimbursement rates starting January 1, 2007.
• Operational Risks: Continued pressure from third-party payers to reduce costs, growth of mail-order pharmacies, and the ability to successfully integrate the Albertson's acquisition.

Investor Verification Checklist

• Acquisition Closing: Verify the status of the $3.93 billion Albertson's acquisition and the satisfaction of Hart-Scott-Rodino Act waiting periods.
• Financing Strategy: Monitor the execution of the planned sale-leaseback transactions and the refinancing of short-term debt into long-term instruments.
• Credit Rating Impact: Assess the impact of recent rating downgrades (Moody's Baa1, S&P BBB+) on future borrowing costs and access to capital markets.
• Margin Pressure: Track the impact of Medicare Part D implementation and Medicaid reimbursement changes on gross margin rates in subsequent quarters.
• Stock Compensation: Review the ongoing impact of SFAS No. 123(R) adoption on operating expenses and net earnings.